PUBLISHER: The Business Research Company | PRODUCT CODE: 1939196
PUBLISHER: The Business Research Company | PRODUCT CODE: 1939196
Advanced drug delivery systems refer to innovative techniques and formulations designed to enhance the targeted distribution, bioavailability, and efficacy of pharmaceutical medications. These systems aim to maximize drug efficacy while minimizing side effects, providing controlled drug release rates, and targeting specific areas of the body.
The main types of advanced drug delivery systems include oral drug delivery systems, injection-based drug delivery systems, inhalation or pulmonary drug delivery systems, transdermal drug delivery systems, transmucosal drug delivery systems, carrier-based drug delivery systems, and others. The oral drug delivery system involves introducing a chemical through the mouth or into the gastrointestinal tract for systemic activity. Carrier types in these systems include liposomes, nanoparticles, microspheres, monoclonal antibodies, and others. Various technologies, such as prodrugs, implants, intrauterine devices, targeted drug delivery, polymeric drug delivery, and others, are employed. These delivery systems find applications in indications such as cardiovascular diseases, oncology, urology, diabetes, central nervous system (CNS) disorders, ophthalmology, inflammatory diseases, infections, and more. They are utilized by hospitals, specialized clinics, and clinical research and development centers.
Tariffs are impacting the advanced drug delivery systems market by increasing costs of imported polymers, nanoparticles, specialty excipients, delivery devices, and precision manufacturing equipment. Pharmaceutical manufacturers in North America and Europe are most affected due to globalized raw material sourcing, while Asia-Pacific faces higher costs in exporting advanced formulations. These tariffs are increasing development and production expenses. However, they are also encouraging regional sourcing of materials, localized manufacturing, and innovation in cost-optimized drug delivery technologies.
The advanced drug delivery systems market research report is one of a series of new reports from The Business Research Company that provides advanced drug delivery systems market statistics, including advanced drug delivery systems industry global market size, regional shares, competitors with a advanced drug delivery systems market share, detailed advanced drug delivery systems market segments, market trends and opportunities, and any further data you may need to thrive in the advanced drug delivery systems industry. This advanced drug delivery systems market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The advanced drug delivery systems market size has grown strongly in recent years. It will grow from $285.59 billion in 2025 to $310.15 billion in 2026 at a compound annual growth rate (CAGR) of 8.6%. The growth in the historic period can be attributed to expansion of pharmaceutical R&D activities, rising prevalence of chronic diseases, advancements in formulation science, growth of injectable drug therapies, increased focus on treatment efficacy.
The advanced drug delivery systems market size is expected to see strong growth in the next few years. It will grow to $433.56 billion in 2030 at a compound annual growth rate (CAGR) of 8.7%. The growth in the forecast period can be attributed to increasing demand for personalized medicine, rising adoption of biologics, expansion of nanotechnology-based therapies, growing focus on reducing drug side effects, increasing investments in advanced pharmaceutical delivery platforms. Major trends in the forecast period include increasing adoption of targeted drug delivery technologies, rising use of nanocarrier-based formulations, growing demand for controlled release systems, expansion of biologic and biosimilar delivery solutions, enhanced focus on patient-centric drug administration.
The anticipated rise in chronic conditions is poised to drive the expansion of the advanced drug delivery systems market. Chronic conditions, persisting for a year or longer and necessitating ongoing medical care, are attributed to various risk behaviors such as tobacco use, exposure to secondhand smoke, poor nutrition, physical inactivity, and excessive alcohol use. Advanced drug delivery systems play a crucial role in precisely delivering therapeutic agents to specific sites affected by chronic conditions, enhancing drug effectiveness, and minimizing side effects. For example, as per May 2023 data from The United Nations (UN), chronic diseases account for seven out of 10 deaths in the US, causing over 1.7 million fatalities annually. Consequently, the increasing prevalence of chronic conditions underpins the growth of the advanced drug delivery systems market.
Leading players in the advanced drug delivery system landscape are prioritizing the development of innovative approaches, including subcutaneous biologic delivery technologies, to address the growing need for convenient, fast, and patient-centric administration of complex therapies. Subcutaneous biologic delivery allows high volumes of medication to be administered beneath the skin, providing a less invasive option compared with conventional intravenous infusions. For example, in June 2023, Halozyme Therapeutics, Inc. announced approval by the United States Food and Drug Administration for VYVGART Hytrulo with ENHANZE, a novel subcutaneous formulation indicated for generalized myasthenia gravis. This product combines efgartigimod alfa with Halozyme's recombinant human hyaluronidase PH20 (rHuPH20), enabling rapid, high-volume subcutaneous administration through a single injection. The approach shortens administration time to seconds, enhances patient convenience, enables treatment beyond hospital settings, and preserves clinical effectiveness comparable to intravenous delivery.
In November 2023, Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on therapies for Alzheimer's disease, entered into a collaboration with Halozyme Therapeutics, Inc. to develop a subcutaneous formulation of ACU193 utilizing ENHANZE technology. Through this collaboration, the companies seek to enhance patient-focused drug delivery by enabling a more convenient and efficient subcutaneous administration of ACU193 while maintaining therapeutic performance. Halozyme Therapeutics, Inc. provides specialized drug delivery solutions, including ENHANZE technology, which supports subcutaneous delivery of biologics and helps reduce the overall treatment burden for patient
Major companies operating in the advanced drug delivery systems market are Pfizer Inc., Johnson and Johnson Services Inc., Roche Holding AG, Abbvie Inc., Bayer AG, Novartis AG, AstraZeneca plc, GlaxoSmithKline plc, 3M Company, Medtronic plc, Eli Lilly and Company, Boehringer Ingelheim GmbH, Amgen Inc., Merck Group, Becton Dickinson and Company, Baxter International Inc., Teva Pharmaceutical Industries Ltd., Sanofi S.A., Boston Scientific Corporation, Astellas Pharma Inc., Catalent Inc., Nipro Corporation, AptarGroup Inc., West Pharmaceutical Services Inc., Gerresheimer AG, Insulet Corporation
North America was the largest region in the advanced drug delivery systems market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the advanced drug delivery systems market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the advanced drug delivery systems market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain
The advanced drug delivery systems market consists of revenues earned by entities by providing stimuli-responsive drug delivery systems, sustained drug delivery systems, targeted drug delivery systems, and nanoparticle-based drug delivery systems. The market value includes the value of related goods sold by the service provider or included within the service offering. The advanced drug delivery systems market also consists of sales of fentanyl transdermal patches, albuterol inhalers, and hydrogels. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Advanced Drug Delivery Systems Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses advanced drug delivery systems market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for advanced drug delivery systems ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The advanced drug delivery systems market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.